Filter by tags: Food and Drug Administration Clear all tag filters
2 news articles found
Belgium’s (Ion Beam Applications (IBA), a leading provider of proton therapy solutions for the treatment of cancer, and US-based NorthStar Medical Radioisotopes, which produces radiopharmaceuticals used for medical imaging and therapeutic applications, on 8 March announced a collaboration to increase global availability of technetium-99m (Tc-99m), the most widely used medical radioisotope. The collaboration enables companies outside the USA to access the Tc-99m Generation Systems (TCM Generation Systems) that utilise NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines.
- Source: NEI Magazine
- Date: Tuesday, 16 March 2021
- Original article: neimagazine.com/news/newsiba-and-northstar-medical-radioisotopes-expand-collaboration-8601282
US-based NorthStar Medical Radioisotopes and Belgium’s Ion Beam Applications (IBA) have signed a contract under which IBA would supply up to eight Rhodotron TT300 HE electron beam accelerators to NorthStar, which has issued purchase orders for the first two units. Six more will be delivered in coming years.
- Source: NEI Magazine
- Date: Thursday, 04 April 2019
- Original article: neimagazine.com/news/newsbelgiums-iba-to-supply-accelerators-to-northstar-7136876